群发资讯网

返回主页
imatinib
伊马替尼
常用释义
英式发音
美式发音
基本释义
  • 伊马替尼
例句
  • 1·OBJECTIVE To study and improve the synthesis of imatinib mesylate.
    目的研究和改进甲磺酸伊马替尼的合成工艺。
  • 2·For 5 years, we followed patients with CMLwho received imatinib as initial therapy.
    我们对接受伊马替尼作为初始治疗的CML患者进行了5年的随访。
  • 3·The most GISTs are drug-resistant when be treated with imatinib which is a molecular targeted drug.
    应用伊马替尼对包含该突变体的肿瘤进行分子靶向治疗,多数患者表现为药物抵抗。
  • 4·These data suggest that treatment with imatinib may be a novel therapeutic approach for cryoglobulinemia and MPGN in humans.
    这些数据表明,伊马替尼治疗可能是一种治疗人类冷球蛋白血症和MPGN的新方法。
  • 5·However, the price at which imatinib has been offered for sale by Novartis around the world has caused me considerable discomfort.
    翻译过来就是,诺华在全球出售伊马替尼的价格搞的我相当的不爽!
  • 6·Of the 192 patients recruited, 129 completed the study; 58 received intermittent treatment and 26 received continuous imatinib treatment.
    在全部192例患者中,129例完成研究,58例接受间断治疗,26例接受持续伊马替尼治疗。
  • 7·Objective to detect the ABL point mutations in chronic myeloid leukemia (CML) patients treated with imatinib by denaturing high-performance liquid chromatography (DHPLC).
    目的应用变性高效液相色谱(DHPLC)检测伊马替尼治疗后慢性髓性白血病(CML)患者ABL激酶区点突变。
  • 8·Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
    选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者:BCR - ABL突变状态是否真的重要?
  • 9·In this article we reviewed the advances in clinical study of imatinib including its mechanism of resistance, adverse events, life quality study and cost-effective analysis, etc.
    本文从耐药机制、不良反应、生活质量考察、药物经济学成本-效用分析等方面综述了其最新临床研究进展。
  • 10·A team of researchers from the U. s. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years.
    包括药物的发明者Brian Druker博士在内的一个由来自美国和欧洲的研究人员组成的团队跟踪研究了454位慢性粒细胞性白血病慢性期患者,这些患者使用伊马替尼已经超过6年。